One could argue that it already has. One drug is enough, one patient is enough.
We’re just getting started.
20.02.2025 00:10
👍 2
🔁 0
💬 1
📌 0
One could argue that it already has. One drug is enough, one patient is enough.
We’re just getting started.
This edit will always live rent free in my head
Duck duck grey duck
(IYKYK)
In a great collaboration with @hummerlab.bsky.social and the Kräusslich lab: HIV capsid doesn't break at the NPC; instead, it cracks open the NPC itself! Details in Cell: authors.elsevier.com/sd/article/S... @mpibp.bsky.social @uniheidelberg.bsky.social A thread below:
In an apparently unprecedented move, Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money. www.statnews.com/2025/01/10/e...
Not something I can answer directly. I assume it’s a time thing, easier to funnel time/energy to the larger mega-round companies we’re seeing more of in biotech?
1 is slow, 2 would be quick.
1 - Make this an expectation in time. Seed/accelerators (eg Nucleate) start the push. The best firms start to do this, and it becomes something to expect.
2 - Create leverage. Companies provide specific metrics or other essential info in exchange for deep feedback
Yeah completely it would be.
To your original point, it comes down to how this gets incentivized. One thing I’ve seen is a founder aggressively coming back and asking for feedback and/or reasoning for a negative decision. So one aspect of this can be to empower founders to do this.
I would worry that a lot of the passes are because they don’t understand, or believe in the differentiation. That’s a tough message to pass on without significant context?
Some of the best advice I got early in my career was that the best scientists “never really turned their brain off”.
This is a perfect description of that. It wasn’t a call to action on working stupid hours, it’s pushing into the creative problem solving needed for complex science.
After nearly three decades, a Minnesota summer camp for kids with HIV/AIDS is closing and up for sale... because retroviral drugs are so effective that there aren't enough campers.
Science works, y'all.
www.startribune.com/closure-of-n...
Huge congratulations to Arbor on their IND clearance!
arbor.bio/arbor-biotec...
Macrophages have a lot of innate pathways to shut down expression from exogenous places. Anecdotally, I’ve seen the same issue of a transduction with no expression on RAW264 cells, but there are ways to design around it: pmc.ncbi.nlm.nih.gov/articles/PMC...
Caribou Biosciences - Jan 2011
Editas Medicine - November 2013
Intellia Therapeutics - November 2014
The American Journal of Human Genetics' latest article reports that nearly one-third of NICU neonates initially not considered appropriate for rapid genetic testing have a genetic disease, highlighting the promise of broad implementation of genome sequencing-based newborn screening.
#ASHG #Genetics
1.0x too, you’re a monster
New starter pack for all people interested in Gene Editing & Gene Therapy 🧬✂️ including Tools & Delivery|CRISPR-Cas|Zinc finger nucleases|Viral vectors|Non-viral delivery methods
go.bsky.app/8R4dVez
Awesome news Aron, congratulations!!
Great thread by Harmit. Industry success (individual and company) also extremely luck dependent… what matters is your *return* on said luck. Graphic and concept from “Great by Choice”.
CNN claiming it may have been targeted
Completely agree on method-dependence here too, especially in HSC populations where DNA repair kinetics will vary greatly throughout the process.
Beautiful paper by Jacob Corn’s lab on the influence of DNA repair on editing outcomes:
www.nature.com/articles/s41...
Although not included, would really be curious to understand the magnitude of the effect in non-cycling cells.
It’s even more basic than this!
Original discovery of the function was in 07’ (pubmed.ncbi.nlm.nih.gov/17379808/) and the e coli locus was in 1987! (pubmed.ncbi.nlm.nih.gov/3316184/)
REALLY cool spatial transcriptomics work by @peruhlen.bsky.social.
www.science.org/doi/10.1126/...
🔥🔥🔥
Mouse serum can bind (and sometimes inactivate) LVV in vivo. Do you think some of this macrophage effect is exacerbated by this? I don’t think AAV8 and APOE LNPs suffer from the same effect in mice
